- PM Modi visit USAOnly the mirror in my washroom and phone gallery see the crazy me : Sara KhanKarnataka rain fury: Photos of flooded streets, uprooted treesCannes 2022: Deepika Padukone stuns at the French Riviera in Sabyasachi outfitRanbir Kapoor And Alia Bhatt's Wedding Pics - Sealed With A KissOscars 2022: Every Academy Award WinnerShane Warne (1969-2022): Australian cricket legend's life in picturesPhotos: What Russia's invasion of Ukraine looks like on the groundLata Mangeshkar (1929-2022): A pictorial tribute to the 'Nightingale of India'PM Modi unveils 216-feet tall Statue of Equality in Hyderabad (PHOTOS)
The 18-year-old, Chirag Chikkara clinched a gold medal in the men’s freestyle 57kg categ
- FIFA president Infantino confirms at least 9 African teams for the 2026 World Cup
- Hockey, cricket, wrestling, badminton, squash axed from 2026 CWG in Glasgow
- FIFA : Over 100 female footballers urge FIFA to reconsider partnership with Saudi oil giant
- Ecuador ready to make history against Uruguay: Beccacece
- Divanshi wins second gold as India sweep women's 25m standard pistol at Lima Junior Worlds
Pharma pricing regulator cuts stent prices by up to 85% Last Updated : 14 Feb 2017 07:06:55 PM IST (File Photo)
In a major measure of relief to cardiac patients in India, the government on Tuesday fixed the ceiling price of coronary stents which are used to open up blocked arteries.
The National Pharmaceutical Pricing Authority, in a notification, put a ceiling price on drug eluting stents (DES) and bioresorbable stents at Rs 29,600, and that of bare metal stents at Rs 7,260, effective from Tuesday. The ceiling price excludes local taxes.
The cost of a drug eluting stent currently ranges between Rs 24,000 and Rs 1.5 lakh, and that of a bioresorbable stent is between Rs 1.7 lakh to Rs 2 lakh. A bare metal stent costs between Rs 7,000 and Rs 20,000.
NPPA said it had consulted with various stakeholders on the matter.
"During deliberations, it was found that huge unethical markups are charged at each stage in the supply chain of coronary stents resulting in irrational, restrictive and exorbitant prices in a failed market system driven by information asymmetry between the patient and doctors pushing patients to financial misery," an NPPA notification said.
The NPPA also said that a stent could cost the patient over ten times more by the time it moved from the manufacturer to the patient.
In July 2016, the Union Health Ministry had, through a notification, included coronary stents under the National List of Essential Medicines (NLEM). Drugs and devices listed in the NLEM have to be sold at the price fixed by NPPA. This was after the Delhi High Court sought government action on a public interest litigation (PIL) appeal seeking price control on stents.IANS For Latest Updates Please-
Join us on
Follow us on
172.31.16.186